^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gallbladder Cancer

    Related cancers:
    3d
    A Case of Gallbladder Cancer Diagnosed by Pathology after Full-Thickness Cholecystectomy and Death Due to Early Recurrence (PubMed, Gan To Kagaku Ryoho)
    A second stage operation was planned, but FDG-PET/CT scans performed 5 weeks after surgery showed ascites and abnormal accumulation suggestive of peritoneal dissemination. The patient subsequently died 4 months after surgery due to progression of the primary disease.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    3d
    Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (clinicaltrials.gov)
    P1/2, N=103, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jul 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Bavencio (avelumab) • peposertib (M3814)
    5d
    Hepatobiliary and Pancreatic Tumor Biobank (clinicaltrials.gov)
    P=N/A, N=300, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    5d
    Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How? (PubMed, J Gastrointest Cancer)
    Molecular testing has become an essential component of modern iCCA management. Broad, early, and technically integrated molecular profiling-ideally performed at initial diagnosis and interpreted in an interdisciplinary (molecular) tumor board-is critical to fully realize the potential of precision oncology in BTC.
    Review • Journal • MSi-H Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • HER-2 amplification • IDH1 mutation • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion
    5d
    GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=93, Recruiting, Fudan University | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial primary completion date
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • oxaliplatin • Zepsun (donafenib)
    7d
    FAPi-2: Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Tata Memorial Centre
    New trial
    7d
    AHNAK2 is a novel diagnostic biomarker for gallbladder adenocarcinoma. (PubMed, Histol Histopathol)
    AHNAK2 demonstrates moderate sensitivity and high specificity in the pathological diagnosis of GBC, particularly for well-differentiated ACs. Combining AHNAK2 with IMP3 significantly enhances diagnostic sensitivity, achieving up to 90% across all AC grades.
    Journal
    |
    AHNAK2 (AHNAK Nucleoprotein 2)
    8d
    CD109 Expression in Tumor and Stromal Cells Serves as a Prognostic Biomarker for Tumor Progression and Outcome in Gallbladder Adenocarcinoma. (PubMed, Pathol Int)
    Moreover, CD109 depletion promoted enhanced transforming growth factor-β1/Smad3 signaling and attenuated epidermal growth factor/AKT signaling in GBAC cells in a cell type-dependent manner. Collectively, these findings suggest that CD109 may serve as a prognostic biomarker of tumor progression and outcome in GBAC.
    Journal
    |
    EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
    10d
    Actionable Genomic Landscape of Biliary Tract Cancer in the Indian Population. (PubMed, Oncologist)
    This study provides a comprehensive molecular profiling of BTCs in the Indian population, revealing key genomic alterations, subtype-specific differences, and associations with immune features. The findings underscore the importance of molecular profiling in guiding personalized treatment strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • KRAS mutation • HER-2 amplification • PIK3CA mutation • IDH1 mutation • ARID1A mutation • STK11 mutation • PD-L1 negative
    10d
    TACTIC: MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (clinicaltrials.gov)
    P2, N=75, Recruiting, Centre Hospitalier Universitaire de Besancon | Not yet recruiting --> Recruiting | Trial completion date: Jun 2029 --> Nov 2029 | Initiation date: Jun 2025 --> Dec 2025 | Trial primary completion date: Jun 2028 --> Nov 2028
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • MP0317
    10d
    IMMCO-1: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types (clinicaltrials.gov)
    P1/2, N=29, Suspended, University of Florida | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative • HR negative + HER-2 positive
    |
    Tecentriq (atezolizumab) • Fotivda (tivozanib)
    11d
    Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer. (PubMed, Cancer Cell)
    Although rare, neuroendocrine GBC was separately characterized, revealing MEIS1 as a potential regulator of neuroendocrine-like features. Together, this study establishes a proteogenomic landscape of GBC, providing biological insights and guiding future translational efforts.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MEIS1 (Meis Homeobox 1) • ELF3 (E74 Like ETS Transcription Factor 3) • ACAT1 (Acetyl-CoA Acetyltransferase 1) • PHGDH (Phosphoglycerate Dehydrogenase)
    |
    TP53 mutation • HER-2 amplification • HER-2 mutation